

CHEST[®]

Official publication of the American College of Chest Physicians



Controversies Over UICC-TNM Classification of Non-small Cell Lung Cancer : Model for a Diagnostic Path

Massimiliano Paci, Giorgio Sgarbi, Guglielmo Ferrari, Salvatore De Franco and Valerio Annessi

Chest 2002;122;754-
DOI 10.1378/chest.122.2.754

The online version of this article, along with updated information and services can be found online on the World Wide Web at:

<http://chestjournal.org>

CHEST is the official journal of the American College of Chest Physicians. It has been published monthly since 1935. Copyright 2007 by the American College of Chest Physicians, 3300 Dundee Road, Northbrook IL 60062. All rights reserved. No part of this article or PDF may be reproduced or distributed without the prior written permission of the copyright holder (<http://www.chestjournal.org/misc/reprints.shtml>). ISSN: 0012-3692.

A M E R I C A N C O L L E G E O F



P H Y S I C I A N S[®]

Controversies Over UICC-TNM Classification of Non-small Cell Lung Cancer

Model for a Diagnostic Path

To the Editor:

The evaluation of a patient with a lung tumor cannot be made separately from the molecular biology of the tumor itself, the presence of growth factors, the presence of inhibitors of tissue invasion, and the development of metastases, tumor suppressor genes, and the presence of dominant oncogenes.¹ Currently, the therapeutic program is based on the rigid staging rules imposed by the TNM classification,² which contrast with the plasticity and singularity of tumors found in individual patients. In the face of this criticism, an increasing number of reports^{3,4} and clinical evidence regard these staging criteria as penalizing patients who are, for example, in advanced stages of disease such as IIIB and IV. Some authors in fact maintain that the TNM classification underestimates the real long-term survival potential in patients with stage T4, resectable lung tumors (*ie*, in the vertebra, superior vena cava, and atrium),^{5,6} stage T4 for double neoplasm in the same lobe,⁷ stage M1 for double intrathoracic ipsilateral or contralateral synchronous neoplasms,⁸ and also for stage M1 disease resulting from sole brain^{9,10} or adrenal metastases.¹¹

From a purely practical point of view, what needs to be established is the most useful diagnostic and therapeutic path for optimizing the available resources and guaranteeing that each individual patient receives the highest diagnostic efficiency as well as the maximum therapeutic efficacy, even in the long term. The current staging proposal, in our opinion, does not reflect these needs, particularly the real long-term survival prospects of patients with advanced-stage lung tumors. Some authors have suggested modifying the International Union Against Cancer (UICC) model by bringing both interesting and useful changes to the interpretation of stage N2 and by introducing the concept of operable stage T4 disease.¹² However, once more the biological behavior of the disease has to be considered, and the problem of the synchronous tumor has not been dealt with. Obviously, the primary objective is "personalized" biological staging in the near future; this is not possible as yet, however, and consequently we must make an effort to create a diagnostic model that reflects as accurately as possible the progress of the lung tumor disease of the patient in question in order to arrive at a histologic definition of stages T, N2, and N3, as well as M, whatever is required and is technically feasible, before imposing a definitive therapeutic program.

After an initial evaluation with chest radiograph and CT scan, we propose carrying out tests that help to reach a histologic diagnosis of a suspect pulmonary neoplasia, including bronchoscopy with brushing and, if necessary, an endoscopic biopsy, transbronchial biopsy, an ultrasound-guided transbronchial biopsy, transthoracic biopsy (ultrasonically or CT-guided), and ultrasound-guided transesophageal biopsy. On completion of the clinical staging, a whole-body positron emission tomography (PET) scan (which has greater sensitivity compared to bone scintigraphy in osteolytic lesions and greater sensitivity compared to CT and ultrasound scanning in secondary hepatic and adrenal lesions^{13,14}) and a CT scan of the brain (because of the low accuracy of PET with 2-[18F]fluoro-2-deoxy-D-glucose in this zone) should be performed.

On the basis of the data supplied by the PET and CT scans of the brain, the following order of staging classification can be made: stage N2, N3, M-negative patients for whom surgical intervention is suggested, subject to a functional evaluation; stage

N2 or N3-positive; stage M-negative patients who need to undergo the necessary procedures (*ie*, mediastinoscopy, mediastinotomy, videothoracoscopy, transtracheal biopsy, transbronchial biopsy, ultrasound-guided transbronchial biopsy, and ultrasound-guided transesophageal biopsy) for the histologic definition of stage N; stage N2 and N3-negative; stage M-positive patients for whom, where possible, a histologic definition of stage M is necessary; stage N2 and M-positive patients in whom tests need to be carried out to obtain a histologic definition of stage M first, wherever possible, and then of stage N2; and, finally, stage N3 and M-positive patients for whom the histologic definition is needed of the most easily obtainable site of stage N3 or M disease. In our opinion, this approach guarantees the reduction of the current overtreatment of patients with stage N3 or M-positive disease, without removing the possibility of increasing the survival of selected patients who are in advanced stages of disease.

Massimiliano Paci, MD

Giorgio Sgarbi, MD

Guglielmo Ferrari, MD

Salvatore De Franco, MD

Valerio Annessi, MD

Santa Maria Nuova Hospital

Reggio Emilia, Italy

Correspondence to: Giorgio Sgarbi, MD, 1st Department of Surgery, Division of Thoracic Surgery, Santa Maria Nuova Hospital, Viale Risorgimento 80, 42100 Reggio Emilia, Italy; e-mail: sgarbi.giorgio@asmn.re.it

REFERENCES

- 1 Bunn PA, Soriano A, Johnson G, et al. New therapeutic strategies for lung cancer. *Chest* 2000; 117:163S-168S
- 2 Mountain CF. Revisions in the International System for Staging Lung Cancer. *Chest* 1997; 111:1711-1717
- 3 Leong SS, Lima CM, Sherman CA, et al. The 1997 International Staging System for non-small cell lung cancer: have all the issues been addressed? *Chest* 1999; 115:242-248
- 4 Okada M, Tsubota N, Yoshimura M, et al. Evaluation of TNM classification for lung carcinoma with ipsilateral intrapulmonary metastasis. *Ann Thorac Surg* 1999; 68:326-330
- 5 Grunewald D, Mazel C, Girard P, et al. Total vertebrectomy for *en bloc* resection of lung cancer invading the spine. *Ann Thorac Surg* 1996; 61:723-725
- 6 Tsuchiya R. Controversy over the UICC-TNM classification. *Nippon Geka Gakkai Zasshi* 2001; 102:502-506
- 7 Kondo K, Monden Y. Controversies in the new TNM staging system. *Nippon Geka Gakkai Zasshi* 1999; 100:700-704
- 8 Vansteenkiste JF, De Belie B, Deneffe GJ, et al. Practical approach to patients presenting with multiple synchronous suspect lung lesions: a reflection on the current TNM classification based on 54 cases with complete follow-up. *Lung Cancer* 2001; 34:169-175
- 9 Bonnette P, Puyo P, Gabriel C, et al. Surgical management of non-small cell lung cancer with synchronous brain metastases. *Chest* 2001; 119:1469-1475
- 10 Billing PS, Miller DL, Allen MS, et al. Surgical treatment of primary lung cancer with synchronous brain metastases. *Thorac Cardiovasc Surg* 2001; 122:548-553
- 11 Porte H, Siat J, Guibert B, et al. Resection of adrenal metastases from non-small cell lung cancer: a multicenter study. *Ann Thorac Surg* 2001; 71:981-985
- 12 Grunewald DH. Surgery for advanced stage lung cancer. *Semin Surg Oncol* 2000; 18:137-142
- 13 Haberkorn U. Positron emission tomography (PET) of non-small cell lung cancer. *Lung Cancer* 2001; 34:S115-121
- 14 Yun M, Kim W, Alnafisi N, et al. 18F-FDG PET in characterizing adrenal lesions detected on CT or MRI. *J Nucl Med* 2001; 42:1795-1799

**Controversies Over UICC-TNM Classification of Non-small Cell Lung
Cancer : Model for a Diagnostic Path**
Massimiliano Paci, Giorgio Sgarbi, Guglielmo Ferrari, Salvatore De Franco and
Valerio Annessi
Chest 2002;122:754-
DOI 10.1378/chest.122.2.754

This information is current as of June 19, 2008

Updated Information & Services	Updated information and services, including high-resolution figures, can be found at: http://chestjournal.org/cgi/content/full/122/2/754
References	This article cites 12 articles, 7 of which you can access for free at: http://chestjournal.org/cgi/content/full/122/2/754#BIBL
Permissions & Licensing	Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: http://chestjournal.org/misc/reprints.shtml
Reprints	Information about ordering reprints can be found online: http://chestjournal.org/misc/reprints.shtml
Email alerting service	Receive free email alerts when new articles cite this article sign up in the box at the top right corner of the online article.
Images in PowerPoint format	Figures that appear in CHEST articles can be downloaded for teaching purposes in PowerPoint slide format. See any online article figure for directions.

